Health Canada and Hoffmann-La Roche Ltd. report cases of severe eye inflammation leading to vision loss following use of AVASTIN in the eye

13/12/2011

Hoffmann-La Roche Ltd (Roche) in consultation with Health Canada has issued a public advisory notice reporting cases of severe eye inflammation leading to blindness following the unauthorized use of AVASTIN® (bevacizumab) in the eye. The use of AVASTIN in the eye is not authorized by Health Canada and was not developed to be injected into the eye. Cases of bacterial infection and inflammation in the eye resulting in blindness or near blindness have been reported in three locations in the United States after patients were injected in the eye with AVASTIN. The cases appear to be due to contamination after repackaging single-use AVASTIN vials into several syringes.

In view of the fact that AVASTIN is not approved by Health Canada for the purpose of treating wet age-related macular degeneration (AMD), and recognizing that some eye doctors may prescribe AVASTIN off-label, CNIB recommends patients consult with their eye doctor to discuss their individual course of treatment. In addition, we recommend that patients consult their eye doctor if they experience any of the symptoms described in the Roche public advisory as a result of an AVASTIN injection in the eye.

For other inquiries related to this communication, or to read the full public notice, visit Healthy Canadians website​.

For inquiries, please contact:

Sarah Snowdon
Specialist, Communications
CNIB
T: (416) 486-2500 ext 7157
E: sarah.snowdon@cnib.ca

Retour au haut de la page